根據(jù)有關(guān)要求,擬對山西醫(yī)科大學(xué)(第3完成單位)的第6完成人崔永萍聯(lián)合申報(bào)北京市科學(xué)技術(shù)獎(jiǎng)材料進(jìn)行公示。公示時(shí)間:8月12日-8月18日。
在公示期內(nèi),任何單位或個(gè)人對公示項(xiàng)目持有異議的,可以書面形式向?qū)W校科學(xué)技術(shù)部反映,并提供必要的證明文件。個(gè)人提出異議的,須在書面異議屬真實(shí)姓名;以單位名義提出異議的,須加蓋本單位公章。
聯(lián)系人:王靜,0351-3985329
公示內(nèi)容:
提名單位:中國醫(yī)學(xué)科學(xué)院
項(xiàng)目名稱:食管鱗癌分子分型基礎(chǔ)及驅(qū)動(dòng)事件的調(diào)控機(jī)制
成果類別:北京市科學(xué)技術(shù)獎(jiǎng)自然科學(xué)獎(jiǎng)
所有完成人:劉芝華、詹啟敏、王明榮、陳洪巖、郝佳潔、崔永萍、趙丫卉、羅擎宇、吳曉巍、魏文強(qiáng)
所有完成單位:中國醫(yī)學(xué)科學(xué)院腫瘤醫(yī)院、北京大學(xué)腫瘤醫(yī)院、山西醫(yī)科大學(xué)
提名意見:
中國醫(yī)學(xué)科學(xué)院腫瘤醫(yī)院劉芝華教授牽頭,與北京大學(xué)腫瘤醫(yī)院和山西醫(yī)科大學(xué)聯(lián)合申報(bào)“北京市科學(xué)技術(shù)獎(jiǎng)”。項(xiàng)目團(tuán)隊(duì)經(jīng)過多年積累和攻關(guān),完成多項(xiàng)國家級重大重點(diǎn)項(xiàng)目,多視角解析癌變分子機(jī)制、多維度鑒定診療標(biāo)志物、多層面構(gòu)建分子分型體系,有力推進(jìn)食管癌精準(zhǔn)診療進(jìn)程。主要?jiǎng)?chuàng)新點(diǎn)如下:
1. 研究策略創(chuàng)新:秉承多組學(xué)、多維度、多層面的研究策略,開展系統(tǒng)性、創(chuàng)新性研究。
2. 基礎(chǔ)理論創(chuàng)新:從基因組和表觀遺傳調(diào)控異常、生物大分子功能穩(wěn)態(tài)失衡的角度,系統(tǒng)揭示了食管癌發(fā)生發(fā)展的分子機(jī)制,具有重要的理論價(jià)值。
3. 技術(shù)突破、應(yīng)用創(chuàng)新:本項(xiàng)目獲得的分子分型標(biāo)志物、新靶點(diǎn)和治療新策略,填補(bǔ)了食管癌應(yīng)用基礎(chǔ)和轉(zhuǎn)化研究的空白,推動(dòng)了食管癌個(gè)體化診療進(jìn)程。
項(xiàng)目團(tuán)隊(duì)在食管癌研究領(lǐng)域深耕多年,協(xié)同攻關(guān),在Cancer Cell、Nat Genet等權(quán)威雜志發(fā)表系列論文,取得了重要?jiǎng)?chuàng)新性成果,引領(lǐng)食管癌基礎(chǔ)和轉(zhuǎn)化研究。
特此提名該項(xiàng)目為北京市科學(xué)技術(shù)獎(jiǎng)自然科學(xué)獎(jiǎng)一等獎(jiǎng)或二等獎(jiǎng)。
代表作發(fā)表情況
Zhihua Liu, Yahui Zhao, Pengzhou Kong, Yuhao Liu, Jing Huang, Enwei Xu, Wenqing Wei, Guangyu Li, Xiaolong Cheng, Liyan Xue, Yi Li, Hongyan Chen, Shuqing Wei, Ruifang Sun, Heyang Cui, Yongsheng Meng, Meilin Liu, Yang Li, Riyue Feng, Xiao Yu, Rui Zhu, Yenan Wu, Lei Li, Bin Yang, Yanchun Ma, Jiawei Wang, Wenjie Zhu, Dongjie Deng, Yanfeng Xi, Fang Wang, Hongyi Li, Shiping Guo, Xiaofei Zhuang, Xiaoyue Wang, Yuchen Jiao, Yongping Cui, Qimin Zhan. Integrated Multi-omics Profiling Yields a Clinically-Relevant Molecular Classification for Esophageal Squamous Cell Carcinoma. Cancer Cell. 2023 Jan 9;41(1):181-195..
Yongping Cui, Hongyan Chen, Ruibin Xi, Heyang Cui, Yahui Zhao, Enwei Xu, Ting Yan, Xiaomei Lu, Furong Huang, Pengzhou Kong, Yang Li, Xiaolin Zhu, Jiawei Wang, Wenjie Zhu, Jie Wang, Yanchun Ma, Yong Zhou, Shiping Guo, Ling Zhang, Yiqian Liu, Bin Wang, Yanfeng Xi, Ruifang Sun, Xiao Yu, Yuanfang Zhai, Fang Wang, Jian Yang, Bin Yang, Caixia Cheng, Jing Liu, Bin Song, Hongyi Li, Yi Wang, Yingchun Zhang, Xiaolong Cheng, Qimin Zhan, Yanhong Li, Zhihua Liu. Whole-genome Sequencing of 508 Patients Identifies Key Molecular Features Associated With Poor Prognosis in Esophageal Squamous Cell Carcinoma. Cell Res. 2020, 30(10):902-913.
Jia-Jie Hao, De-Chen Lin, Huy Q Dinh, Anand Mayakonda, Yan-Yi Jiang, Chen Chang, Ye Jiang, Chen-Chen Lu, Zhi-Zhou Shi, Xin Xu, Yu Zhang, Yan Cai, Jin-Wu Wang, Qi-Min Zhan, Wen-Qiang Wei, Benjamin P Berman, Ming-Rong Wang, H Phillip Koeffler. Spatial intratumoral heterogeneity and temporal clonal evolution in esophageal squamous cell carcinoma. Nat Genet. 2016,48(12):1500-1507.
Qingyu Luo, Xiaowei Wu, Wan Chang, Pengfei Zhao, Yabing Nan, Xiaolin Zhu, Jonathan P Katz, Dan Su, Zhihua Liu. ARID1A prevents squamous cell carcinoma initiation and chemoresistance by antagonizing pRb/E2F1/c-Myc-mediated cancer stemness. Cell Death Differ. 2020,27(6):1981-1997.
Qingyu Luo, Xiaowei Wu, Pengfei Zhao, Yabing Nan, Wan Chang, Xiaolin Zhu, Dan Su, Zhihua Liu. OTUD1 Activates Caspase-Independent and Caspase-Dependent Apoptosis by Promoting AIF Nuclear Translocation and MCL1 Degradation. Adv Sci (Weinh). 2021,8(8):2002874.